S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
5 Short Squeeze Candidates With Catalysts For Rebounds

Sarepta Therapeutics (SRPT) Stock Forecast, Price & News

$120.45
+1.86 (+1.57%)
(As of 10/3/2023 ET)
Compare
Today's Range
$117.71
$121.08
50-Day Range
$102.50
$123.59
52-Week Range
$100.15
$159.89
Volume
916,141 shs
Average Volume
831,680 shs
Market Capitalization
$10.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$173.70

Sarepta Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
44.2% Upside
$173.70 Price Target
Short Interest
Bearish
5.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.78mentions of Sarepta Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$4.79 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($9.20) to ($1.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

294th out of 965 stocks

Pharmaceutical Preparations Industry

112th out of 450 stocks


SRPT stock logo

About Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

SRPT Price History

SRPT Stock News Headlines

Are Gene Therapy Stocks The Market's Next Big Winners? (SRPT)
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Insiders Are Buying These 2 Stocks (SRPT)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Sarepta Therapeutics (NASDAQ:SRPT) Given Buy Rating at Mizuho
Sarepta Therapeutics Inc
Sarepta Therapeutics (NASDAQ: SRPT)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
2 Top Growth Stocks to Buy With $500
SRPT Aug 2023 102.000 call
Is Sarepta Therapeutics Stock a Top Growth Vehicle?
Massive Insider Trade At Sarepta Therapeutics
Sarepta Therapeutics (SRPT) Gets a Buy from Mizuho Securities
See More Headlines
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Company Calendar

Last Earnings
8/02/2023
Today
10/04/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
1,162
Year Founded
1980

Price Target and Rating

Average Stock Price Forecast
$173.70
High Stock Price Forecast
$223.00
Low Stock Price Forecast
$125.00
Forecasted Upside/Downside
+44.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
15 Analysts

Profitability

Net Income
$-703,490,000.00
Pretax Margin
-88.20%

Debt

Sales & Book Value

Annual Sales
$933.01 million
Book Value
$4.39 per share

Miscellaneous

Free Float
81,488,000
Market Cap
$10.60 billion
Optionable
Optionable
Beta
0.93

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Douglas S. Ingram Esq.Mr. Douglas S. Ingram Esq. (Age 60)
    Pres, CEO & Director
    Comp: $1.62M
  • Mr. Ian Michael Estepan (Age 47)
    Exec. VP & CFO
    Comp: $917.53k
  • Dr. Louise R. Rodino-Klapac Ph.D. (Age 45)
    Exec. VP, Chief Scientific Officer and Head of R&D
    Comp: $1.04M
  • Mr. Ryan E. Brown J.D. (Age 45)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $823.36k
  • Mr. Bilal Arif (Age 51)
    Exec. VP & Chief Technical Operations Officer
  • Mary Jenkins
    Sr. Mang. of Investor Relations
  • Ms. Alison Nasisi
    Exec. VP & Chief People Officer
  • Dr. Diane L. Berry Ph.D.
    Exec. VP and Chief of Global Policy & Advocacy Officer
  • Mr. Dallan Murray
    Exec. VP & Chief Customer Officer
  • Mr. Will Tilton
    Sr. VP, Head of Strategy & Chief of Staff













SRPT Stock - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SRPT shares.
View SRPT analyst ratings
or view top-rated stocks.

What is Sarepta Therapeutics' stock price forecast for 2023?

15 brokers have issued 12-month price targets for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $125.00 to $223.00. On average, they anticipate the company's stock price to reach $173.70 in the next twelve months. This suggests a possible upside of 44.2% from the stock's current price.
View analysts price targets for SRPT
or view top-rated stocks among Wall Street analysts.

How have SRPT shares performed in 2023?

Sarepta Therapeutics' stock was trading at $129.58 on January 1st, 2023. Since then, SRPT shares have decreased by 7.0% and is now trading at $120.45.
View the best growth stocks for 2023 here
.

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our SRPT earnings forecast
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($1.89) by $1.62. The biotechnology company earned $261.20 million during the quarter, compared to analysts' expectations of $255.99 million. Sarepta Therapeutics had a negative net margin of 90.46% and a negative trailing twelve-month return on equity of 91.22%. The company's revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the company posted ($2.65) earnings per share.

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $120.45.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $10.60 billion and generates $933.01 million in revenue each year. The biotechnology company earns $-703,490,000.00 in net income (profit) each year or ($10.31) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

The company employs 1,162 workers across the globe.

Does Sarepta Therapeutics have any subsidiaries?
The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.
Read More
How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.

This page (NASDAQ:SRPT) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -